# Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma

> **NCT00165217** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 37 (—)

## Conditions studied

- Colorectal Adenocarcinoma

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00165217
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 37 (—)
- **Last updated:** 2007-12-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165217, "Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00165217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*